MX2017015297A - Metodos para reducir o prevenir daño a la intima provocado por estimulacion mecanica de celulas endoteliales. - Google Patents
Metodos para reducir o prevenir daño a la intima provocado por estimulacion mecanica de celulas endoteliales.Info
- Publication number
- MX2017015297A MX2017015297A MX2017015297A MX2017015297A MX2017015297A MX 2017015297 A MX2017015297 A MX 2017015297A MX 2017015297 A MX2017015297 A MX 2017015297A MX 2017015297 A MX2017015297 A MX 2017015297A MX 2017015297 A MX2017015297 A MX 2017015297A
- Authority
- MX
- Mexico
- Prior art keywords
- mechanical stimulation
- endothelial cells
- damage caused
- methods
- reducing
- Prior art date
Links
- 230000000638 stimulation Effects 0.000 title abstract 3
- 210000002889 endothelial cell Anatomy 0.000 title abstract 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 101000844504 Homo sapiens Transient receptor potential cation channel subfamily M member 4 Proteins 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 abstract 1
- 210000001736 capillary Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000003462 vein Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/104—Balloon catheters used for angioplasty
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Modalidades de la descripción abarcan métodos y/o composiciones para mejorar o prevenir daño a la íntima provocado por estimulación mecánica de células endoteliales. El daño puede ser provocado mediante el uso de un dispositivo dentro de una arteria, vena o capilar de un individuo, tal como para remover un trombo, un émbolo o una placa aterosclerótica en el vaso. Modalidades de tratamiento y prevención conciernen a cantidades terapéuticamente efectivas de uno o más antagonistas del canal SUR1 - TRPM4 que es sobrerregulado sobre la estimulación mecánica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562168589P | 2015-05-29 | 2015-05-29 | |
PCT/US2016/034066 WO2016196113A1 (en) | 2015-05-29 | 2016-05-25 | Methods of reducing or preventing intimal damage caused by mechanical stimulation of endothelial cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017015297A true MX2017015297A (es) | 2018-06-19 |
Family
ID=57441652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017015297A MX2017015297A (es) | 2015-05-29 | 2016-05-25 | Metodos para reducir o prevenir daño a la intima provocado por estimulacion mecanica de celulas endoteliales. |
Country Status (14)
Country | Link |
---|---|
US (1) | US10900040B2 (es) |
EP (1) | EP3302514B1 (es) |
JP (2) | JP6973752B2 (es) |
KR (1) | KR102618123B1 (es) |
CN (1) | CN108348567B (es) |
AU (1) | AU2016271576B2 (es) |
CA (1) | CA2988417C (es) |
EA (1) | EA038398B1 (es) |
ES (1) | ES2927482T3 (es) |
HK (1) | HK1252532A1 (es) |
IL (1) | IL255875A (es) |
MA (1) | MA45307A (es) |
MX (1) | MX2017015297A (es) |
WO (1) | WO2016196113A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX363473B (es) | 2012-05-08 | 2019-03-25 | Aeromics Inc | Uso de fenilbenzamidas para tratar condiciones mediadas por acuaporina. |
US20160279155A1 (en) | 2013-11-06 | 2016-09-29 | Aeromics, Inc. | Novel formulations |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998057651A1 (en) * | 1997-06-18 | 1998-12-23 | Discovery Therapeutics, Inc. | Compositions and methods for preventing restenosis following revascularization procedures |
WO2006036278A2 (en) * | 2004-09-18 | 2006-04-06 | University Of Maryland, Baltimore | THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF |
EP2114160B1 (en) * | 2007-02-09 | 2016-11-16 | University of Maryland, Baltimore | Antagonists of a non-selective cation channel in neural cells |
US8557867B2 (en) * | 2007-06-22 | 2013-10-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Inhibitors of NCCa-ATP channels for therapy |
WO2009073711A1 (en) | 2007-12-04 | 2009-06-11 | Remedy Pharmaceuticals, Inc. | Improved formulations and methods for lyophilization and lyophilates provided thereby |
KR20220000943A (ko) | 2010-07-19 | 2022-01-04 | 바이오젠 체사피크 엘엘씨 | 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법 |
-
2016
- 2016-05-25 MA MA045307A patent/MA45307A/fr unknown
- 2016-05-25 CN CN201680031454.2A patent/CN108348567B/zh active Active
- 2016-05-25 WO PCT/US2016/034066 patent/WO2016196113A1/en active Application Filing
- 2016-05-25 ES ES16804027T patent/ES2927482T3/es active Active
- 2016-05-25 CA CA2988417A patent/CA2988417C/en active Active
- 2016-05-25 AU AU2016271576A patent/AU2016271576B2/en active Active
- 2016-05-25 US US15/577,273 patent/US10900040B2/en active Active
- 2016-05-25 EP EP16804027.7A patent/EP3302514B1/en active Active
- 2016-05-25 EA EA201792569A patent/EA038398B1/ru unknown
- 2016-05-25 KR KR1020177037774A patent/KR102618123B1/ko active IP Right Grant
- 2016-05-25 JP JP2018513732A patent/JP6973752B2/ja active Active
- 2016-05-25 MX MX2017015297A patent/MX2017015297A/es unknown
-
2017
- 2017-11-23 IL IL255875A patent/IL255875A/en unknown
-
2018
- 2018-09-14 HK HK18111842.7A patent/HK1252532A1/zh unknown
-
2021
- 2021-07-07 JP JP2021112461A patent/JP2021167335A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2018516981A (ja) | 2018-06-28 |
US20180155727A1 (en) | 2018-06-07 |
AU2016271576A1 (en) | 2018-01-04 |
CN108348567B (zh) | 2022-03-01 |
CN108348567A (zh) | 2018-07-31 |
US10900040B2 (en) | 2021-01-26 |
CA2988417C (en) | 2022-10-11 |
EA038398B1 (ru) | 2021-08-23 |
EA201792569A1 (ru) | 2018-04-30 |
MA45307A (fr) | 2018-04-11 |
JP2021167335A (ja) | 2021-10-21 |
IL255875A (en) | 2018-01-31 |
EP3302514B1 (en) | 2022-07-06 |
EP3302514A4 (en) | 2019-04-24 |
KR102618123B1 (ko) | 2023-12-27 |
AU2016271576B2 (en) | 2021-10-07 |
EP3302514A1 (en) | 2018-04-11 |
KR20180035741A (ko) | 2018-04-06 |
ES2927482T3 (es) | 2022-11-07 |
HK1252532A1 (zh) | 2019-05-31 |
JP6973752B2 (ja) | 2021-12-01 |
CA2988417A1 (en) | 2016-12-08 |
WO2016196113A1 (en) | 2016-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273824A (en) | Methods of using ehmt2 inhibitors in the treatment or prevention of blood disorders | |
ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
MX2017000307A (es) | Tratamiento de leucemia con inhibidores de histona deacetilasa. | |
GT201700134A (es) | Inhibidores de erk | |
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
MA40437A (fr) | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux | |
MX2021010528A (es) | Metodos y composiciones para el tratamiento de las ulceras. | |
CR20160308A (es) | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores | |
MD4801B1 (ro) | Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice | |
MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
MX2015006478A (es) | Inhibidores de glutaminasa y metodos de empleo. | |
MY184106A (en) | Treatment of dna damage and mitochondrial dysfunction using palm fruit juice | |
TR201900319T4 (tr) | C1 esteraz inhibitör eksikliği ile ilişkili bozuklukların önlenmesinde ve tedavisinde kullanım için c1-inh bileşimleri ve yöntemler. | |
PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
TN2017000465A1 (en) | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) | |
MX2017006019A (es) | Apilimod para uso en el tratamiento de melanoma. | |
MX2016016793A (es) | Discos de aireacion y metodos para usar los mismos. | |
MX2017015297A (es) | Metodos para reducir o prevenir daño a la intima provocado por estimulacion mecanica de celulas endoteliales. | |
NZ724799A (en) | Compositions and methods for the treatment or prevention of neurodegenerative disorders | |
EA201790537A1 (ru) | Дипептидилкетоамидные соединения и их применение для лечения и/или предотвращения накопления жира | |
HK1246205A1 (zh) | 在預防和/或治療皮膚損傷中使用的至少一種蛋白酶抑制劑和至少一種活性成分的組合 | |
IL247616B (en) | Centrally acting acetylcholinesterase inhibitors for the prevention/or treatment of chemically induced neurodegenerative diseases and their symptoms, and corresponding compositions, uses, methods and kit |